← Back to All US Stocks

MWAI Stock Analysis 2026 - MedWellAI, Inc. AI Rating

MWAI OTC Finance Services NV CIK: 0001520118
Recently Updated • Analysis: Apr 12, 2026 • SEC Data: 2025-12-31
STRONG SELL
97% Conf
Pending
Analysis scheduled

📊 MWAI Key Takeaways

Revenue: $1.1M
Net Margin: -87.3%
Free Cash Flow: $-255.7K
Current Ratio: 0.02x
Debt/Equity: N/A
EPS: $-0.45
AI Rating: STRONG SELL with 97% confidence

Is MWAI a Good Investment? Thesis Analysis

Claude

MedWellAI is technically insolvent with negative stockholders' equity of -$7.5M and a fundamentally broken business model evidenced by -65.4% gross margin. The company is burning cash at -$255.7K annually with critically poor liquidity (0.02x current ratio) and lacks any viable path to profitability without severe restructuring or capital injection.

Why Buy MWAI? Key Strengths

Claude
  • + Still maintaining minimal cash reserves of $137.5K
  • + Modest asset base of $460.9K reduces absolute downside exposure
  • + Low revenue base provides theoretical capacity for growth if business model corrects

MWAI Investment Risks to Consider

Claude
  • ! Negative stockholders' equity of -$7.5M indicates technical insolvency
  • ! Negative gross margin of -65.4% proves business model is fundamentally unviable
  • ! Severe cash burn of -$255.7K annually with only $137.5K cash remaining
  • ! Critically impaired liquidity: 0.02x current ratio indicates inability to meet short-term obligations
  • ! Debt burden of $328.0K unsustainable relative to assets and cash generation
  • ! No insider activity in 90 days suggests lack of management confidence

Key Metrics to Watch

Claude
  • * Gross margin trajectory - must turn positive to validate business viability
  • * Operating cash flow - must cease negative cash burn immediately
  • * Stockholders' equity - must return to positive territory
  • * Current ratio and liquidity position - critical to assess solvency risk

MWAI Financial Metrics

Revenue
$1.1M
Net Income
$-939.4K
EPS (Diluted)
$-0.45
Free Cash Flow
$-255.7K
Total Assets
$460.9K
Cash Position
$137.5K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

MWAI Profitability Ratios

Gross Margin -65.4%
Operating Margin -55.8%
Net Margin -87.3%
ROE N/A
ROA -203.8%
FCF Margin -23.8%

MWAI vs Finance Sector

How MedWellAI, Inc. compares to Finance sector averages

Net Margin
MWAI -87.3%
vs
Sector Avg 25.0%
MWAI Sector
ROE
MWAI 0.0%
vs
Sector Avg 12.0%
MWAI Sector
Current Ratio
MWAI 0.0x
vs
Sector Avg 1.2x
MWAI Sector
Debt/Equity
MWAI 0.0x
vs
Sector Avg 2.0x
MWAI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is MWAI Overvalued or Undervalued?

Based on fundamental analysis, MedWellAI, Inc. has mixed fundamental signals relative to the Finance sector in 2026.

Return on Equity
N/A
Sector avg: 12%
Net Profit Margin
-87.3%
Sector avg: 25%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 2x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

MWAI Balance Sheet & Liquidity

Current Ratio
0.02x
Quick Ratio
0.01x
Debt/Equity
N/A
Debt/Assets
1,682.1%
Interest Coverage
-22.59x
Long-term Debt
$328.0K

MWAI 5-Year Financial Trend & Growth Analysis

MWAI 5-year financial data: Year 2021: Revenue $1.9M, Net Income -$1.1M, EPS N/A. Year 2022: Revenue $6.6M, Net Income -$22.4M, EPS N/A. Year 2023: Revenue $6.6M, Net Income -$565.5K, EPS N/A. Year 2024: Revenue $5.9M, Net Income -$25.5M, EPS $-11.98. Year 2025: Revenue $594.8K, Net Income -$11.5M, EPS N/A.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: MedWellAI, Inc.'s revenue has declined by 68% over the 5-year period, indicating business contraction. The most recent EPS of $-11.98 indicates the company is currently unprofitable.

MWAI Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-23.8%
Free cash flow / Revenue

MWAI Quarterly Performance

Quarterly financial performance data for MedWellAI, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q2 2026 $142.9K -$287.5K N/A
Q1 2026 $1.1K -$651.9K N/A
Q3 2025 $281.3K $297.3K $0.01
Q2 2025 $142.9K -$359.6K $-0.13
Q1 2025 $1.1K -$1.2M N/A
Q3 2024 $1.5M $297.3K $0.01
Q2 2024 $370.3K -$354.3K $-0.13
Q1 2024 $555.4K -$786.4K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

MWAI Capital Allocation

Operating Cash Flow
-$255.7K
Cash generated from operations
Stock Buybacks
$34.0M
Shares repurchased (TTM)
Dividends Paid
$293.6K
Returned to shareholders

MWAI SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for MedWellAI, Inc. (CIK: 0001520118)

📋 Recent SEC Filings

Date Form Document Action
Feb 23, 2026 10-Q intv_10q.htm View →
Nov 14, 2025 10-Q intv_10q.htm View →
Sep 30, 2025 10-K intv_10k.htm View →
Aug 7, 2025 8-K intv_8k.htm View →
Jun 24, 2025 8-K intv_8k.htm View →

Frequently Asked Questions about MWAI

What is the AI rating for MWAI?

MedWellAI, Inc. (MWAI) has an AI rating of STRONG SELL with 97% confidence, based on fundamental analysis of SEC EDGAR filings.

What are MWAI's key strengths?

Claude: Still maintaining minimal cash reserves of $137.5K. Modest asset base of $460.9K reduces absolute downside exposure.

What are the risks of investing in MWAI?

Claude: Negative stockholders' equity of -$7.5M indicates technical insolvency. Negative gross margin of -65.4% proves business model is fundamentally unviable.

What is MWAI's revenue and growth?

MedWellAI, Inc. reported revenue of $1.1M.

Does MWAI pay dividends?

MedWellAI, Inc. pays dividends, with $0.3M distributed to shareholders in the trailing twelve months.

Where can I find MWAI SEC filings?

Official SEC filings for MedWellAI, Inc. (CIK: 0001520118) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is MWAI's EPS?

MedWellAI, Inc. has a diluted EPS of $-0.45.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is MWAI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, MedWellAI, Inc. has a STRONG SELL rating with 97% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is MWAI stock overvalued or undervalued?

Valuation metrics for MWAI: ROE of N/A (sector avg: 12%), net margin of -87.3% (sector avg: 25%). Compare these metrics with sector averages to assess valuation.

Should I buy MWAI stock in 2026?

Our dual AI analysis gives MedWellAI, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is MWAI's free cash flow?

MedWellAI, Inc.'s operating cash flow is $-255.7K, with capital expenditures of $0.0. FCF margin is -23.8%.

How does MWAI compare to other Finance stocks?

Vs Finance sector averages: Net margin -87.3% (avg: 25%), ROE N/A (avg: 12%), current ratio 0.02 (avg: 1.2).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 12, 2026 | Data as of: 2025-12-31 | Powered by Claude AI